This is a working overview of MC4R agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
R-NH2 + DBNPA → R-NH-C(Br)(NO2)NH2 In basic environments, DBNPA undergoes nucleophilic substitution by hydroxide ions, which initiates hydrolysis. This reaction reduces the environmental persistence of DBNPA by breaking it down into smaller degradation products.
=== Gulf War === Hitchens deplored and opposed the 1990–91 Gulf War in which the US expelled Iraq from Kuwait after a seven-month invasion and occupation of its neighbor undertaken in an effort to absorb it as its 19th province. He contended that President George H. W. Bush's supposedly principled enthusiasm for the "cause" of "liberating" Kuwait was nothing more than realpolitik. In the continuation of a national policy dating back to Henry Kissinger and Richard Nixon in 1972, the latest "cause was yet another move in the policy of keeping a region divided and embittered, and therefore accessible to the franchisers of weaponry and the owners of black gold". However, after the war, Hitchens scolded those within the US who had opposed the war by observing that "the peace movement in this country in my opinion acted in a very narrow, isolationist, and almost chauvinistic way. It said that a war was more or less alright with it as long as it could be guaranteed in advance that American casualties could be kept low... I thought that was a dishonourably narrow way of approaching the question. ... When large numbers of Iraqis were turned into soap...and many others, as we've since found out, were bulldozed and buried alive and in other ways done away with and people don't even want to think about the body count ...because they're afraid of what they might find out."
In Ethiopia and Zambia, elaborate scarification is often done on women at puberty, used to denote a willingness to be a mother. The markings show that she can stand the pain of childbirth, as well as being an indication of her emotional maturity.
Artocarpus lacucha, also known as monkey jack or monkey fruit, is a tropical evergreen tree species of the family Moraceae. It is distributed throughout the Indian subcontinent and Southeast Asia. The tree is valued for its wood; its fruit is edible and is believed to have medicinal value. In Northeastern Thailand, the wood is used to make pong lang, a local traditional instrument. This tree is mentioned in the Arthashastra.
17 November – Anton Hull, a drink-driver who filmed himself at the wheel saying he was "smashed" then went on to bill 29-year-old Sarah Baker in a crash in Somerset, is sentenced to six years imprisonment and given a nine-year driving ban. 18 November – Businesses in London have urged the UK government to relax Sunday trading hours because of the cost of living crisis, estimating longer trading hours would generate an extra £300m a year. A study of Bradford's Pakistani community finds that cousin marriage has dropped sharply over the past decade, with 60% of parents born to cousins ten years ago compared to 46% now. Ice hockey team Nottingham Panthers play their first game since the death of Adam Johnson. The Adam Johnson Memorial Game is played against Manchester Storm. 19 November – An earthquake measuring 2.7 magnitude strikes parts of Cornwall at 12.50am. 20 November – Four men are convicted of the August 2022 murder of Ashley Dale in Liverpool following a disagreement involving her boyfriend. 21 November – North Hertfordshire Museum announces it will reclassify the Roman Emperor Elagabalus as a trans woman in its display about the historical figure because classical texts claim the emperor once said "call me not Lord, for I am a Lady". 22 November – James Witham, Joseph Peers, Niall Barry, and Sean Zeisz are each sentenced to life imprisonment with minimum terms of over 40 years for the murder of Ashley Dale. 23 November – A man is shot dead by armed police in Dagenham after telling Met officers he wanted to kill himself and had loaded guns.
Sources: en.wikipedia.org
Myelinoclastic or demyelinating disorders: Typical forms of multiple sclerosis Neuromyelitis optica, or Devic's disease Idiopathic inflammatory demyelinating diseases Leukodystrophic or dysmyelinating disorders: CNS neuropathies such as those produced by vitamin B12 deficiency Central pontine myelinolysis Myelopathies such as tabes dorsalis (syphilitic myelopathy) Leukoencephalopathies such as progressive multifocal leukoencephalopathy Leukodystrophies The myelinoclastic disorders are typically associated with symptoms such as optic neuritis and transverse myelitis, because the demyelinating inflammation can affect the optic nerve or spinal cord. Many are idiopathic. Both myelinoclastic and leukodystrophic modes of disease may result in lesional demyelinations of the central nervous system.
== Early life and education == Ingram Cecil Connor III was born in Winter Haven, Florida, to Ingram Cecil Connor II, aka "Coon Dog", and Avis Snively Connor. He had one sibling, a sister. Connor II was a World War II flying ace, decorated with the Air Medal, who worked at his father-in-law's company and was a local Boy Scout official. Both parents were alcoholics and both suffered from depression; Cecil II shot and killed himself on December 23, 1958. Avis then married Robert Parsons, whose surname was adopted by Gram and his sister. Avis and Robert would have one child, Parsons's half-sister. Avis was the daughter of citrus fruit magnate John A. Snively, who held extensive properties in Winter Haven, Florida and Waycross, Georgia, where the Connors normally lived. Parsons attended The Bolles School in Jacksonville before transferring to the public Winter Haven High School; after failing his junior year there, he returned to Bolles. On his graduation day, June 5, 1965, his mother died of complications from alcoholism. Robert Parsons had been having an affair with Gram's half-sister's nanny; they married shortly after Avis's death. Gram went on to Harvard University, which he attended for one semester. At age 21, he began to receive his annual trust fund income of $30,000 ($289,671 in 2025).
== Prognosis == Kwashiorkor is associated with a high risk of mortality and long-term complications. Treatment under the guidelines of the World Health Organization has proven to reduce this mortality risk and affected children tend to recover faster than children with other severe malnutrition diseases. However, physical and intellectual capabilities are not fully restored. Growth stunting and chronic disruption of microbiota are commonly observed after recovery. A high risk of death is identified by a brachial perimeter < 11 cm or by a weight-for-age threshold < −3 z-scores below the median of the WHO child growth standards. In practice, malnourished children with edema are suffering from potentially life-threatening severe malnutrition.
=== Societies and administration === The International Union of Basic and Clinical Pharmacology, Federation of European Pharmacological Societies, and European Association for Clinical Pharmacology and Therapeutics are organizations representing standardization and regulation of clinical and scientific pharmacology. Systems for medical classification of drugs with pharmaceutical codes have been developed. These include the National Drug Code (NDC), administered by Food and Drug Administration; Drug Identification Number (DIN), administered by Health Canada under the Food and Drugs Act; Hong Kong Drug Registration, administered by the Pharmaceutical Service of the Department of Health (Hong Kong), and National Pharmaceutical Product Index in South Africa. Hierarchical systems have also been developed, including the Anatomical Therapeutic Chemical Classification System (AT, or ATC/DDD), administered by World Health Organization; Generic Product Identifier, a hierarchical classification number published by MediSpan and SNOMED, C axis. Ingredients of drugs have been categorized by Unique Ingredient Identifiers.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.